More men with long-term opioid use are screened for low testosterone than men taking opioids for a short period of time; however, given the known link between opioid use and low testosterone, these rates were still lower than expected.
For women aged 50 to 59 years with a history of bilateral oophorectomy, estrogen therapy may have beneficial effects in the long-term.
Testosterone can be used for postmenopausal women with hypoactive sexual desire dysfunction (HSDD) but is not recommended for other symptoms or medical conditions.
Use of menopausal hormonal therapy for 5 years around the start of menopause may be associated with increased risk for breast cancer.
Vyleesi (bremelanotide injection; AMAG Pharmaceuticals) is now commercially available through specialty pharmacies, Avella and BioPlus.
There is an association between the number of concussion symptoms at the time of injury and the odds of reporting indicators of low testosterone level and erectile dysfunction among former football players.
Men with elevated serum sex hormone-binding globulin or lower total testosterone levels might be at greater risk for cardiovascular disease.
Exogenous estrogen preparations may have different effects on heart fat accumulation and development of coronary artery calcification in early menopausal women.
Women with premature ovarian insufficiency (POI) receiving hormone therapy have poor sleep quality.
Testosterone therapy has been found to improve sexual function in postmenopausal women, but the lack of approved formulations for women in any country remains a major barrier to treatment.
